• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

激活SUR2B/Kir6.1型钾通道对肾细胞损伤的干预作用及其机制

[Interventional effects of activating SUR2B/Kir6.1-type K channels on renal cells injury and its mechanisms].

作者信息

Zhao Ying, Wang Hai

机构信息

Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing 100853.

Research Division of Pharmacology, the Fifth Medical Center of PLA General Hospital, Beijing 100853, China.

出版信息

Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2022 Nov;38(6):604-610. doi: 10.12047/j.cjap.6356.2022.110.

DOI:10.12047/j.cjap.6356.2022.110
PMID:37308403
Abstract

To investigate the interventional effects of a new SUR2B/Kir6.1-type K Channel opener iptakalim on injury renal cells (the renal glomerular endothelial, mesangial and tubular epithelial cells) and its mechanisms. ①Experimental protocol: control: the cells were treated with with 0 mg/L uric acid for 24 h; model: the cells were treated with with 1 200 mg/L uric acid for 24 h; pretreatment with iptakalim: the cells were pretreated with 0.01,0.1,1,10,100 μmol/L iptakalim for 24 h prior to treatment with 1 200 mg/L uric acid for 24 h; pretreatment with glibenclamide: the cells were preincubated with/without 10 μmol/L glibenclamide for 1 h and then treated with 10 μmol/L iptakalim for 24 h followed by incubation with 1 200 mg/L uric acid for another 24 h. ②The cell viability was measured by MTT assay and flow cytometry; the protein expressions of Kir6.1 and SUR2B and nuclear translocation were detected by immunostaining; the protein expressions of Kir6.1 and SUR2B were determined by Western blot analysis; adhesion of mononuclear cells to endothelial cells were tested by fluorimetric assay; the content of MCP-1 was measured by enzyme linked-immunosorbent assay (ELISA). The renal glomerular endothelial, mesangial and tubular epithelial cells were exposed to 1 200 mg/L uric acid for 24 h. Compared with the control group, 1 200 mg/L uric acid decreased the cell survival rates significantly (<0.01, <0.01, <0.01). Compared with the model group, pretreatment with 0.1, 1, 10, 100 μmol/L iptakalim could remarkably alleviate cellular damages of glomerular endothelium, mesangium cells induced by uric acid (<0.05, <0.01, <0.01, <0.01). The K channel blocker could clearly reduce survival rates of the renal glomerular endothelial, mesangial cells(<0.01) and markedly reverse the inhibitory effects of iptakalim on cell death (<0.05, <0.01), no obvious difference in comparison with the model group (>0.05). Compared with the model group, pretreatment with 10, 100 μmol/L iptakalim could notably attenuate cellular damages of tubular epithelial cells induced by uric acid (<0.05, <0.05). The K channel blocker could obviously damage the tubular epithelial cells (<0.01), no obvious difference in comparison with the model group (>0.05). Compared with control group, exposure of renal tubular epithelial, mesangial and glomerular endothelial cells to 1 200 mg/L uric acid for 24 h caused a significant increase in the protein expressions of Kir6.1 and SUR2B(<0.05). Compared with the model group, the overexpressions of Kir6.1 and SUR2B were suppressed in presence of iptakalim at a concentration of 10 μmol/L (<0.05). These decreases in the expressions of Kir6.1 and SUR2B were prevented by the K channel blocker, no obvious difference in comparison with the model group (>0.05). Compare with the control group, monocytic adhesion to renal glomerular endothelial cells was notably promoted by 1 200 mg/L uric acid for 24 h (<0.01). Pretreatment with 10 μmol/L iptakalim for 24 h significantly reduced the monocytic adhesion in comparison with the model group (<0.05). It was showed that the inhibitory effects of iptakalim were antagonized by the K channel blocker, no obvious difference in comparison with the model group (>0.05). After stimulating glomerular endothelial cells with 1 200 mg/L uric acid for 24 hours, the secretion of MCP-1 was significantly increased compared to the control group (<0.05). Compare with the model group, preincubation with 10 μmol/L iptakalim significantly decreased MCP-1 production (<0.05). K channel blocker suppressed the downregulation of MCP-1 protein synthesis induced by iptakalim. After stimulation with uric acid, translocation of NF-κB from cytoplasms to nuclei of renal glomerular endothelial cells were observed, while that of NF-κB was suppressed in presence of iptakalim at the concentration of 10 μmol/L. This inhibition of NF-κB translocation was clearly prevented by K channel blocker. These results suggests that a new SUR2B/Kir6.1-type K channel opener iptakalim plays interventional roles in renal cells damages caused by uirc acid and its mechanism is involved in activating Kchannels .

摘要

探讨新型SUR2B/Kir6.1型钾通道开放剂伊伐卡林对损伤肾细胞(肾小球内皮细胞、系膜细胞和肾小管上皮细胞)的干预作用及其机制。①实验方案:对照组:细胞用0mg/L尿酸处理24小时;模型组:细胞用1200mg/L尿酸处理24小时;伊伐卡林预处理组:细胞在用1200mg/L尿酸处理24小时前,先用0.01、0.1、1、10、100μmol/L伊伐卡林预处理24小时;格列本脲预处理组:细胞先在有无10μmol/L格列本脲的条件下预孵育1小时,然后用10μmol/L伊伐卡林处理24小时,接着再用1200mg/L尿酸孵育24小时。②采用MTT法和流式细胞术检测细胞活力;通过免疫染色检测Kir6.1和SUR2B的蛋白表达及核转位;用蛋白质印迹分析测定Kir6.1和SUR2B的蛋白表达;通过荧光测定法检测单核细胞与内皮细胞的黏附;用酶联免疫吸附测定法(ELISA)检测MCP-1的含量。将肾小球内皮细胞、系膜细胞和肾小管上皮细胞暴露于1200mg/L尿酸中24小时。与对照组相比,1200mg/L尿酸显著降低细胞存活率(<0.01,<0.01,<0.01)。与模型组相比,用0.1、1、10、100μmol/L伊伐卡林预处理可显著减轻尿酸诱导的肾小球内皮、系膜细胞的细胞损伤(<0.05,<0.01,<0.01,<0.01)。钾通道阻滞剂可明显降低肾小球内皮、系膜细胞的存活率(<0.01),并显著逆转伊伐卡林对细胞死亡的抑制作用(<0.05,<0.01),与模型组相比无明显差异(>0.05)。与模型组相比,用10、100μmol/L伊伐卡林预处理可显著减轻尿酸诱导的肾小管上皮细胞的细胞损伤(<0.05,<0.05)。钾通道阻滞剂可明显损伤肾小管上皮细胞(<0.01),与模型组相比无明显差异(>0.05)。与对照组相比,将肾小管上皮细胞、系膜细胞和肾小球内皮细胞暴露于1200mg/L尿酸中24小时可导致Kir6.1和SUR2B的蛋白表达显著增加(<0.05)。与模型组相比,在10μmol/L伊伐卡林存在的情况下,Kir6.1和SUR2B的过表达受到抑制(<0.05)。钾通道阻滞剂可阻止Kir6.1和SUR2B表达的这些降低,与模型组相比无明显差异(>0.05)。与对照组相比,1200mg/L尿酸处理24小时可显著促进单核细胞对肾小球内皮细胞的黏附(<0.01)。用10μmol/L伊伐卡林预处理24小时与模型组相比可显著降低单核细胞黏附(<0.05)。结果表明,钾通道阻滞剂可拮抗伊伐卡林的抑制作用,与模型组相比无明显差异(>0.05)。用1200mg/L尿酸刺激肾小球内皮细胞24小时后,与对照组相比,MCP-1的分泌显著增加(<0.05)。与模型组相比,用10μmol/L伊伐卡林预孵育可显著降低MCP-1的产生(<0.05)。钾通道阻滞剂抑制了伊伐卡林诱导的MCP-1蛋白合成的下调。尿酸刺激后,观察到肾小球内皮细胞核因子κB从细胞质向细胞核的转位,而在10μmol/L伊伐卡林存在的情况下,核因子κB的转位受到抑制。钾通道阻滞剂可明显阻止这种核因子κB转位的抑制作用。这些结果表明,新型SUR2B/Kir6.1型钾通道开放剂伊伐卡林对尿酸引起的肾细胞损伤具有干预作用,其机制与激活钾通道有关。

相似文献

1
[Interventional effects of activating SUR2B/Kir6.1-type K channels on renal cells injury and its mechanisms].激活SUR2B/Kir6.1型钾通道对肾细胞损伤的干预作用及其机制
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2022 Nov;38(6):604-610. doi: 10.12047/j.cjap.6356.2022.110.
2
Activation of SUR2B/Kir6.1-type K(ATP) channels protects glomerular endothelial, mesangial and tubular epithelial cells against oleic acid renal damage.SUR2B/Kir6.1型钾离子通道激活可保护肾小球内皮细胞、系膜细胞和肾小管上皮细胞免受油酸肾损伤。
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2012 Nov;28(6):572-6.
3
Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia.ATP敏感性钾通道的激活可保护血管内皮细胞免受高尿酸血症诱导的高血压和肾损伤。
J Hypertens. 2008 Dec;26(12):2326-38. doi: 10.1097/HJH.0b013e328312c8c1.
4
Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim.以一种新的三磷酸腺苷敏感性钾通道开放剂伊帕立林靶向治疗高血压。
J Cardiovasc Pharmacol. 2010 Sep;56(3):215-28. doi: 10.1097/FJC.0b013e3181e23e2b.
5
Rapid Characterization of the Functional and Pharmacological Consequences of Cantú Syndrome K Channel Mutations in Intact Cells.快速鉴定完整细胞中 Cantú 综合征钾通道突变的功能和药理学后果。
J Pharmacol Exp Ther. 2023 Sep;386(3):298-309. doi: 10.1124/jpet.123.001659. Epub 2023 Aug 1.
6
Acute exposure of methylglyoxal leads to activation of KATP channels expressed in HEK293 cells.急性接触甲基乙二醛可导致 HEK293 细胞中表达的 KATP 通道激活。
Acta Pharmacol Sin. 2014 Jan;35(1):58-64. doi: 10.1038/aps.2013.122. Epub 2013 Oct 14.
7
Iptakalim, a vascular ATP-sensitive potassium (KATP) channel opener, closes rat pancreatic beta-cell KATP channels and increases insulin release.伊卡利姆是一种血管ATP敏感性钾(KATP)通道开放剂,可关闭大鼠胰腺β细胞的KATP通道并增加胰岛素释放。
J Pharmacol Exp Ther. 2007 Aug;322(2):871-8. doi: 10.1124/jpet.107.121129. Epub 2007 May 23.
8
A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells.一种新型ATP敏感性钾通道开放剂可保护培养的主动脉内皮细胞的内皮功能。
Cardiovasc Res. 2007 Feb 1;73(3):497-503. doi: 10.1016/j.cardiores.2006.10.007. Epub 2006 Oct 14.
9
Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells.药理学证据:通过内皮细胞中的SUR2B/Kir6.1通道治疗慢性心力衰竭的新治疗方法。
Acta Pharmacol Sin. 2017 Jan;38(1):41-55. doi: 10.1038/aps.2016.118. Epub 2016 Nov 28.
10
[Molecular of pulmonary arterioles relaxation through SUR2B/Kir6.1 channel opening].通过SUR2B/Kir6.1通道开放实现肺小动脉舒张的分子机制
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2016 Mar 8;32(3):238-241. doi: 10.13459/j.cnki.cjap.2016.03.013.